Literature DB >> 26621161

The association of neutrophil to lymphocyte ratio with presence and severity of obstructive sleep apnea.

M Sunbul, E A Sunbul, B Kanar, O Yanartas, S Aydin, A Bacak, H Gulec, I Sari.   

Abstract

BACKGROUND: Obstructive sleep apnea (OSA) is characterized by reductions in breathing amplitude during sleep caused by an obstructed or collapsed upper airway. The neutrophil to lymphocyte ratio (NLR) has been proposed as a novel biomarker for systemic inflammatory response. The aim of the present study was to evaluate the relationship between NLR and OSA.
METHODS: The study population consisted of 195 consecutive patients with clinical suspicion of OSA. Full night polysomnography was performed for all patients. Patients with an apnea hypopnea index (AHI) ≥ 5 were considered to have OSA. NLR was calculated as the ratio of neutrophil count to lymphocyte count.
RESULTS: While 130 patients (91 male, mean age: 49.9±9.8 years) had OSA, 65 patients (42 male, mean age: 48.7 ± 10.2 years) had normal findings according to AHI scores. Cardiovascular risk factors such as hypertension, hyperlipidemia, diabetes mellitus and smoking were more common in patients with OSA. Patients with OSA had significantly higher NLR than controls (1.87±0.80 vs 1.49±0.48, p=0.005). AHI score was significantly correlated with NLR (r=0.228, p=0.001). NLR and presence of hyperlipidemia were independent predictors of OSA (OR: 2.451, 2.850, p=0.001, 0.004, respectively). NLR of 1.62 or higher predicted OSA with a sensitivity of 56.2 % and specificity of 63.1 %.
CONCLUSIONS: NLR was higher and also correlated with AHI score in patients with OSA which has not been reported previously. NLR more than 1.62 was an independent predictor of OSA. A simple, cheap white blood cell count may also give an idea about the presence and severity of OSA (Tab. 3, Fig. 3, Ref. 30).

Entities:  

Keywords:  cardiovascular risk; inflammation; neutrophil to lymphocyte ratio; obstructive sleep apnea.

Mesh:

Year:  2015        PMID: 26621161     DOI: 10.4149/bll_2015_125

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  6 in total

1.  Treatment of obstructive sleep apnea with CPAP improves chronic inflammation measured by neutrophil-to-lymphocyte ratio.

Authors:  Moh'd Al-Halawani; Christian Kyung; Fei Liang; Ian Kaplan; Jane Moon; Guerrier Clerger; Bruce Sabin; Andrea Barnes; Mohammad Al-Ajam
Journal:  J Clin Sleep Med       Date:  2020-01-13       Impact factor: 4.062

2.  Comparison of anatomic and aerodynamic characteristics of the upper airway among edentulous mild, moderate, and severe obstructive sleep apnea in older adults.

Authors:  Hui Chen; Emami Elham; Yingguang Li; Shaohua Ge; Matthieu Schmittbuhl; Gilles Lavigne; Paul F van der Stelt; Nelly Huynh
Journal:  J Clin Sleep Med       Date:  2022-03-01       Impact factor: 4.062

3.  Neutrophil-to-lymphocyte ratio decreases in obstructive sleep apnea treated with mandibular advancement devices.

Authors:  Moh'd Al-Halawani; Sreelatha Naik; Michael Chan; Iouri Kreinin; Jonathan Meiers; Meir Kryger
Journal:  Sleep Breath       Date:  2018-02-07       Impact factor: 2.816

Review 4.  The hematologic consequences of obesity.

Authors:  Johanna C Purdy; Joseph J Shatzel
Journal:  Eur J Haematol       Date:  2020-12-13       Impact factor: 2.997

5.  Association between the neutrophil-to-lymphocyte ratio and obstructive sleep apnea: a meta-analysis.

Authors:  Min-Seok Rha; Chang-Hoon Kim; Joo-Heon Yoon; Hyung-Ju Cho
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

6.  The Neutrophil to Lymphocyte Ratio Is Associated With the Risk of Subsequent Dementia in the Framingham Heart Study.

Authors:  Jaime Ramos-Cejudo; Andrew D Johnson; Alexa Beiser; Sudha Seshadri; Joel Salinas; Jeffrey S Berger; Nathanael R Fillmore; Nhan Do; Chunlei Zheng; Zanetta Kovbasyuk; Babak A Ardekani; Omonigho M Bubu; Ankit Parekh; Antonio Convit; Rebecca A Betensky; Thomas M Wisniewski; Ricardo S Osorio
Journal:  Front Aging Neurosci       Date:  2021-11-30       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.